跳轉至內容
Merck
全部照片(3)

Key Documents

G117

Sigma-Aldrich

格列吡嗪

solid

同義詞:

1-环己基-3-{4-[2-(5-甲基吡嗪-2-甲酰胺基)乙基]苯磺酰基}脲

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C21H27N5O4S
CAS號碼:
分子量::
445.54
EC號碼:
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

形狀

solid

顏色

white

溶解度

methanol: 1.9 mg/mL
DMSO: 48 mg/mL

SMILES 字串

Cc1cnc(cn1)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3

InChI

1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)

InChI 密鑰

ZJJXGWJIGJFDTL-UHFFFAOYSA-N

基因資訊

尋找類似的產品? 前往 產品比較指南

一般說明

钾内向整流通道,亚家族J,成员1(KCNJ1)可编码肾外髓质钾通道(ROMK1,Kir1.1)。 格列吡嗪是一种抗糖尿病药,可用于治疗II型糖尿病。(5)

應用

格列吡嗪已被用于:
  • 雏鸡卵黄囊膜(YSM)和绒膜尿囊膜(CAM)检测
  • 在绒毛膜尿囊膜(CAM)上进行的MCF-7乳腺癌检测
  • 转移测定
  • 大鼠主动脉环测定
  • 体内基质胶塞测定
  • 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四氮唑(MTT)测定
  • 流式细胞术
  • 蛋白印迹

生化/生理作用

钾内向整流通道,亚家族J,成员1(KCNJ1)在钾平衡中起着至关重要的作用。 它是一种ATP依赖的K+通道阻断剂。其所编码的蛋白质负责消除钾,以交换钠被上皮钠通道(ENaC)吸收。 KCNJ1中的突变与多种疾病有关,例如产前Bartter综合征和糖尿病。 格列吡嗪通过预防血管生成,有助于抑制肿瘤的发展和转移。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis
Qi C, et al.
Scientific reports, 6(20), 27819-27819 (2016)
KCNJ1 inhibits tumor proliferation and metastasis and is a prognostic factor in clear cell renal cell carcinoma
Guo Z, et al.
Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine, 36(2), 1251-1259 (2015)
Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment
Karnes JH, et al.
The Pharmacogenomics Journal, 13(5), 430-430 (2013)
K M Pantalone et al.
Diabetes, obesity & metabolism, 14(9), 803-809 (2012-04-11)
It remains uncertain if differences in mortality risk exist among the sulfonylureas, especially in patients with documented coronary artery disease (CAD). The purpose of this study was to assess the overall mortality risk of the individual sulfonylureas versus metformin in
Greg L Plosker
Drugs, 72(17), 2289-2312 (2012-11-23)
Dapagliflozin (Forxiga®) is the first in a novel class of glucose-lowering agents known as sodium-glucose co-transporter-2 (SGLT2) inhibitors and is used in the treatment of patients with type 2 diabetes. By inhibiting the transporter protein SGLT2 in the kidneys, dapagliflozin

文章

Glucose metabolism is regulated by the opposing actions of insulin and glucagon. Insulin is released from pancreatic ß cells in response to high blood glucose levels and regulates glucose metabolism through its actions on muscle, liver, and adipose tissue.

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務